Compositions and methods for immunotherapy
US11267901B2 · kind B2 · utility
7Cited by
1References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 11, 2015 |
| Grant date | Mar 8, 2022 |
| Priority date | — |
| Expiry date | Mar 27, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing an antigen recognizing receptor and an inhibitory chimeric antigen receptor (iCAR). Methods of using the immunoresponsive cell include those for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.